Fiche publication
Date publication
février 2022
Journal
Cells
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
,
Dr LADOIRE Sylvain
,
Dr LIMAGNE Emeric
,
Dr GALLAND Loïck
Tous les auteurs :
Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S
Lien Pubmed
Résumé
Thanks to their anti-inflammatory, anti-oedema, and anti-allergy properties, glucocorticoids are among the most widely prescribed drugs in patients with cancer. The indications for glucocorticoid use are very wide and varied in the context of cancer and include the symptomatic management of cancer-related symptoms (compression, pain, oedema, altered general state) but also prevention or treatment of common side effects of anti-cancer therapies (nausea, allergies, etc.) or immune-related adverse events (irAE). In this review, we first give an overview of the different clinical situations where glucocorticoids are used in oncology. Next, we describe the current state of knowledge regarding the effects of these molecules on immune response, in particular anti-tumour response, and we summarize available data evaluating how these effects may interfere with the efficacy of immunotherapy using immune checkpoint inhibitors.
Mots clés
cancer, corticosteroids, immune checkpoint inhibitors, immune-related adverse event, immunotherapy
Référence
Cells. 2022 Feb 22;11(5):
